{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:59:30Z","timestamp":1793336370039,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013806","name":"Shenyang Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejmech.2024.116488","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:18:41Z","timestamp":1715185121000},"page":"116488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance"],"prefix":"10.1016","volume":"272","author":[{"given":"Xiaoxuan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116488_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2024.116488_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116488_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/03602532.2019.1632886","article-title":"Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it","volume":"51","author":"Verma","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2024.116488_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2017.03.007","article-title":"Potential role of CYP1B1 in the development and treatment of metabolic diseases","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116488_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111938","article-title":"Synthesis and structure-activity relationship studies of alpha-naphthoflavone derivatives as CYP1B1 inhibitors","volume":"187","author":"Dong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/dmd.119.086892","article-title":"Nitidine chloride-induced CYP1 enzyme inhibition and alteration of estradiol metabolism","volume":"47","author":"Mao","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2024.116488_bib7","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.7150\/jca.42669","article-title":"CYP1B1 gene: implications in glaucoma and cancer","volume":"11","author":"Alsubait","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116488_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151598","article-title":"CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of wnt\/beta-catenin signaling via Sp1 upregulation","volume":"11","author":"Kwon","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116488_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.fct.2017.10.051","article-title":"Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: selective bioactivation of luteolin in breast cancer cells","volume":"110","author":"Wilsher","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2024.116488_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3892\/ijmm.2014.2041","article-title":"CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro","volume":"35","author":"Zhu","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116488_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.bjc.6604195","article-title":"CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance","volume":"98","author":"Martinez","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116488_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-2952(01)00643-8","article-title":"Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance","volume":"62","author":"McFadyen Mc","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116488_bib13","first-page":"537","article-title":"Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?","volume":"296","author":"Rochat B","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116488_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmech.2017.02.016","article-title":"Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: overcoming cisplatin resistance in CYP1B1-overexpressing lines","volume":"129","author":"Horley","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1039\/C9MD00258H","article-title":"Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents","volume":"10","author":"Dong","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2024.116488_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113733","article-title":"Overcoming Taxol-resistance in A549 cells: a comprehensive strategy of targeting P-gp transporter, AKT\/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin","volume":"171","author":"Lin","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116488_bib17","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2024.116488_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.cell.2016.08.014","volume":"166","author":"Kleiger G","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116488_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116488_bib20","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2024.116488_bib23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116488_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116488_bib25","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116488_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116488_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105295","article-title":"\u03b1-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: structure activity relationship","volume":"116","author":"Chen P","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112028","article-title":"Design and synthesis of alpha-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation","volume":"189","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib29","doi-asserted-by":"crossref","first-page":"16451","DOI":"10.1021\/acs.jmedchem.2c01306","article-title":"Structure-based drug design and synthesis of novel N-Aryl-2,4-bithiazole-2-amine CYP1B1-selective inhibitors in overcoming Taxol resistance in A549 cells","volume":"65","author":"Mao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095716","article-title":"miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression","volume":"9","author":"Chatterjee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116488_bib31","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/acsmedchemlett.9b00372","article-title":"Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116488_bib33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib34","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acschembio.7b00485","article-title":"Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116488_bib35","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2024.116488_bib36","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1alpha interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116488_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11030-017-9750-y","article-title":"QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1alpha","volume":"21","author":"Pan","year":"2017","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2024.116488_bib38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116488_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245986","article-title":"A compressive review about Taxol((R)): history and future challenges","volume":"25","author":"Gallego-Jara","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116488_bib40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00204-015-1524-7","article-title":"Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity","volume":"89","author":"Suda","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2024.116488_bib41","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/1061186X.2019.1585437","article-title":"NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt\/mTOR signalling pathway","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2024.116488_bib42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116488_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112843","article-title":"One molecule two goals: a selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells","volume":"208","author":"Contino","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116488_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4161\/gmic.1.5.12925","article-title":"The interaction of gut microbes with host ABC transporters","volume":"1","author":"Mercado-Lubo","year":"2010","journal-title":"Gut Microb."},{"key":"10.1016\/j.ejmech.2024.116488_bib46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1126\/science.aar7389","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"359","author":"K","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116488_bib47","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","article-title":"Defining the hallmarks of metastasis","volume":"79","author":"Welch","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116488_bib48","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.cell.2011.11.016","article-title":"Cancer invasion and the microenvironment: plasticity and reciprocity","volume":"147","author":"Friedl","year":"2011","journal-title":"Cell"},{"issue":"Pt 16","key":"10.1016\/j.ejmech.2024.116488_bib49","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1242\/jcs.112.16.2677","article-title":"Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration","volume":"112","author":"Sieg","year":"1999","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2024.116488_bib50","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.18632\/oncotarget.2397","article-title":"Overcoming EMT-associated resistance to anti-cancer drugs via Src\/FAK pathway inhibition","volume":"5","author":"Wilson","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116488_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41419-019-1633-y","article-title":"Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells","volume":"10","author":"Fan","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.116488_bib52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbrc.2009.03.079","article-title":"HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line","volume":"382","author":"Yang","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116488_bib53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1242\/jcs.183699","article-title":"The mechanical regulation of integrin-cadherin crosstalk organizes cells, signaling and forces","volume":"129","author":"Mui","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2024.116488_bib54","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-07-1263","article-title":"A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer","volume":"13","author":"Gravdal","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116488_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1242\/jcs.100115","article-title":"E-cadherin-integrin crosstalk in cancer invasion and metastasis","volume":"126","author":"Canel","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2024.116488_bib56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejmech.2018.05.049","article-title":"Benzo[d]thiazole-2-carbanilides as new anti-TB chemotypes: design, synthesis, biological evaluation, and structure-activity relationship","volume":"155","author":"Dhameliya","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib58","doi-asserted-by":"crossref","first-page":"9229","DOI":"10.1021\/acs.jmedchem.8b00907","article-title":"Targeting cytochrome P450 (CYP) 1B1 enzyme with four series of A-ring substituted estrane derivatives: design, synthesis, inhibitory activity, and selectivity","volume":"61","author":"Dutour","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116488_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095716","article-title":"miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression","volume":"9","author":"Chatterjee","year":"2014","journal-title":"PLoS One"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:43:34Z","timestamp":1717235014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":59,"alternative-id":["S0223523424003684"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116488","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116488"}}